Pembrolizumab with axitinib for untreated advanced renal cell carcinoma: Final appraisal document

Pembrolizumab with axitinib is not recommended, within its marketing authorisation, for untreated advanced renal cell carcinoma in adults because it is uncertain if there is a long-term benefit and it is unlikely to be cost effective at its current price.

Source:

National Institute for Health and Care Excellence